Skip to main content

Table 4 Serious adverse events during 3 years follow-up in the placebo and adipose-derived stromal cell (ASC) group

From: Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results

Serious adverse events Placebo (n = 20) ASC (n = 40) P-value
Death 0 (0) 4 (10) 0.291
Hospitalizations
 Myocardial infarction 5 (25) 8 (20) 0.744
 Dyspnea 0 (0) 1 (2.5) 1.000
 Anemia 2 (10) 3 (7.5) 1.000
 Syncope 1 (5) 0 (0) 0.333
 Peripheral edema 0 (0) 1 (2.5) 1.000
 Angina worsening 12 (60) 14 (35) 0.028
 Pneumonia 1 (5) 4 (10) 0.656
 PCI 7 (35) 6 (15) 0.101
 Heart failure 0 (0) 4 (10) 0.291
 TIA/apoplexia cerebri 2 (10) 0 (0) 0.107
 Pulmonary embolism 0 (0) 1 (5) 1.000
 Cancer 3 (15) 1 (5) 0.103
  1. Values are n (%); P values are calculated using Fischer’s exact test except for angina worsening, which is calculated using Chi-square test
  2. PCI percutaneous coronary intervention, TIA transient ischemic attack